Semaglutide and weight loss – a concern for diabetics and pharmaceuticals
Madam, On 4 June 2021, the FDA approved intravenous Wegovy (semaglutide) for weight-loss management in chronically obese individuals [1]. However, Wegovy, also sold under the name Ozempic, has long been a shortcut for rapid weight loss and gained a reputation as “the worst kept secret in Hollywoo...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Pakistan Medical Association
2024-05-01
|
| Edice: | Journal of the Pakistan Medical Association |
| Témata: | |
| On-line přístup: | https://jpma.org.pk/index.php/public_html/article/view/10705 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|